Brokers Offer Predictions for Immatics FY2025 Earnings

Immatics N.V. (NASDAQ:IMTX) – Investment analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Immatics in a research note issued on Monday, October 13th. Chardan Capital analyst Y. Livshits forecasts that the company will earn ($1.47) per share for the year. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share.

A number of other brokerages also recently weighed in on IMTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a report on Wednesday, October 8th. Zacks Research raised shares of Immatics from a “strong sell” rating to a “hold” rating in a report on Monday. Finally, Guggenheim started coverage on shares of Immatics in a report on Thursday, September 18th. They set a “buy” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.67.

Immatics Price Performance

Shares of Immatics stock opened at $10.20 on Thursday. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $11.25. The firm has a fifty day moving average price of $7.03 and a two-hundred day moving average price of $5.89. The company has a market cap of $1.24 billion, a PE ratio of -15.69 and a beta of 1.22.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.28). Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%. The company had revenue of $6.48 million during the quarter, compared to the consensus estimate of $13.05 million.

Hedge Funds Weigh In On Immatics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its holdings in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after acquiring an additional 2,231 shares during the period. Vontobel Holding Ltd. acquired a new stake in shares of Immatics during the 2nd quarter worth about $59,000. Exchange Traded Concepts LLC increased its position in shares of Immatics by 94.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 25,580 shares of the company’s stock worth $115,000 after purchasing an additional 12,425 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Immatics during the 2nd quarter worth about $124,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Immatics during the 2nd quarter worth about $136,000. 64.41% of the stock is owned by institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.